Document is current
Any future updates will be listed below
-
Authors
Kuruvilla, Deena E.
Mann, Joseph I.
Tepper, Stewart J.
Starling, Amaal J.
Panza, Gregory
Johnson, Michael A. L.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02787551 at ClinicalTrials.govDocuments that mention this clinical trial
1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)
https://doi.org/10.2337/db19-1139-p
149-OR: LixiLan-G: A Randomized Trial Assessing Switching to iGlarLixi vs. Continuation of Daily or Weekly GLP-1RA in T2D Inadequately Controlled by a GLP-1RA and OAD(s)
https://doi.org/10.2337/db19-149-or
88-LB: Similar Efficacy and Safety of IGlarLixi When Initiated in Patients with Type 2 Diabetes (T2D) with or without Concomitant Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Use in a Randomized Controlled Trial (RCT) and Real-World Setting
https://doi.org/10.2337/db20-88-lb
Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
https://doi.org/10.2337/cd17-0065
Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM)
https://doi.org/10.1038/s41598-022-09071-6
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
https://doi.org/10.2337/dc19-1357
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study (Results)
https://doi.org/10.2337/dc20-2023
Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results
https://doi.org/10.1007/s13300-021-01180-1
1146-P: Switching to iGlarLixi vs. Continued Treatment of GLP-1RA: Comparative Analysis by Daily or Weekly GLP-1RAs in the LixiLan-G Trial
https://doi.org/10.2337/db19-1146-p
-
Funding
Funding for this research was provided by:
CEFALY Technologies
- License Information
-
More Information
Article History
Received: 7 July 2021
Accepted: 16 February 2022
First Online: 24 March 2022
Competing interests
: Dr. Deena Kuruvilla has received consulting fees from Amgen, Lily, Allergan, and GLG Consulting Group. Dr Joseph Mann has no conflicting interests. Dr. Stewart Tepper reports grants for research (no personal compensation) from Allergan/Abbvie, Amgen, Eli Lilly, Lundbeck, Neurolief, Novartis, Satsuma, and Zosano, consultant and/or Advisory Boards (honoraria) from Aeon, Allergan/Abbvie, Alphasights, Amgen, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting ClearView Healthcare Partners, CoolTech, CRG, Currax, DRG, Eli Lilly, ExpertConnect, FCB Health, GLG, Guidepoint Global, Health Science Communications, HMP Communications, Impel, InteractiveForums, Krog and Partners, Lundbeck, M3 Global Research, MJH Holdings, Neurolief, Novartis, Palion Medical, Pulmatrix, SAI MedPartners, Satsuma, Spherix Global Insights, Strategy Inc, System Analytic, Taylor and Francis, Teva, Theranica, Unity HA, XOC, and Zosano, salary from Dartmouth-Hitchcock Medical Center, American Headache Society, and Thomas Jefferson University, and CME honoraria from the American Academy of Neurology, American Headache Society, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, Peerview, Medical Education Speakers Network, Migraine Association of Ireland, North American Center for CME, The Ohio State University, Physicians’ Education Resource, PlatformQ Education, Primed, Texas Neurological Society, and WebMD/Medscape. Dr. Amaal J. Starling has received consulting fees from Allergan, Amgen, Axsome Therapeutics, Eli Lilly & Company, Everyday Health, Impel, Lundbeck, Med-IQ, Medscape, Neurolief, Novartis, Satsuma, Teva, and Theranica Dr. Gregory Panza has no conflicting interests. Dr Michael A.L. Johnson is the Global Director of Medical Affairs for CEFALY Technology. All other authors do not have any competing interest.
